Current Trading

PROTEOME SCIENCES plc                             

                                 PRESS RELEASE                                 

                                Current Trading                                

 
21 December 2007.  In the company's interim statement which was released on the
28th September, 2007 details were given about the introduction of isobaric
tandem mass tags (TMT®) to the market and of the expected timing of the
conclusion of outlicencing agreements for this product.

The trade launch for TMT® got underway in November and early indications are
that the product has been well received.

Draft licence proposals for TMT® have been put to the company from a number of
major players, and these proposals are now being finalised in order to conclude
an exclusive licence agreement in the field of isobaric tandem mass tags.

 

The existing loan facility from Christopher Pearce, the Chief Executive of the
group, has not yet been fully drawn down, and it has also been agreed that this
facility may be increased, subject to any necessary regulatory approvals.

 

Against this background, the Board continues to view future prospects for TMT®
commercialisation with increasing confidence, though it is possible that such
licence negotiations may not now be completed until the early part of 2008,
rather than at the end of 2007 as previously indicated.

 

                                     Ends                                      

Notes to editors:

 

Proteome Sciences plc applies high sensitivity proteomics to identify and
characterise differential protein expression in diseases for diagnostic,
prognostic and therapeutic applications.  It has discovered blood biomarkers
principally for stroke, vCJD, BSE, brain damage, solid organ transplant
rejection and Alzheimer's disease. The main focus of its research currently
addresses neurological, neurodegenerative, oncology and cardiovascular
conditions.

 

In addition to its own proprietary biomarkers, Proteome Sciences has developed
ProteoSHOP® (Proteome Sciences High Output Proteomics), a toolbox that offers
high sensitivity and high throughput gel and gel-free proprietary technologies
for the identification and validation of potential biomarkers and drug targets,
including specialisation in membrane proteins and protein phosphorylation. 
ProteoSHOP® also provides for the rapid establishment of quantitative and
highly reproducible portable mass spectrometric assays for proteins and
peptides.

 

The Company has developed a range of specialist reagents to improve the
performance and quantitation of protein separation and characterisation with
mass spectrometry, bioinformatics, statistics and pattern recognition. These
include Sensitizer®, PST®, qPST™ and TMT®.  Proteome Sciences has patent
allowances in the major global jurisdictions for isobaric tandem mass tags (TMT
®) for the manufacture and use of any type of isobaric mass tags.

 

Commercialisation is actively pursued across the portfolio of the Company's
programmes and technologies with licensing deals signed in biomarkers for
Stroke and TSEs and for ProteoSHOP®.

 

Proteome Sciences has its headquarters in Cobham, Surrey in the UK and has
laboratories at Kings College Hospital, London and Frankfurt Innovations
Zentrum (FIZ), Frankfurt. It employs 32 full time scientists in addition to its
corporate and business development staff, and has collaborative research
agreements with leading academic institutes. The Company is listed on the
Alternative Investment Market.

 

For further information please visit www.proteomics.com.

 
Proteome Sciences plc
Christopher Pearce, Chief Executive Officer     James Malthouse, Finance Director
Email: [e-mail]        Email: [e-mail]
Tel: [phone]

                               Public Relations

IKON Associates                                 Coast Communications
Adrian Shaw                                     Matt Baldwin
Tel: [phone]                         Tel: [phone]
Mobile: [phone]                      Mobile: [phone]
Email: [e-mail]                Email: [e-mail]

Nominated Adviser
Teather & Greenwood
Gareth Price / Thilo Hoffman Tel: [phone]